Routine anticonvulsants for treating cerebral malaria.
BACKGROUND
Cerebral malaria is a common complication of Plasmodium falciparum infection, and kills over a million people every year. People with cerebral malaria become unconscious, and often have protracted convulsions. It is unclear whether giving anticonvulsant drugs routinely to people with cerebral malaria will improve the outcome of treatment and prevent death.


OBJECTIVE
To evaluate the effect of routine anticonvulsant drugs in people with cerebral malaria.


METHODS
We searched the Cochrane Infectious Diseases Group specialized trials register (November 2001), The Cochrane Controlled Trials Register (Issue 4, 2001), MEDLINE (1966 to November 2001), EMBASE (1988 to October 2001), LILACS (2001, 40a Edition CD-ROM), Science Citation Index (November 2001), African Index Medicus (1999), reference lists of articles, and research organizations. We also contacted the authors for addtional information.


METHODS
Randomized and quasi-randomized controlled trials of people with cerebral malaria. The trials compared anticonvulsant drugs started on admission to hospital with no anticonvulsant drug or placebo.


METHODS
Two reviewers independently extracted data from those trials eligible for inclusion. We assessed the methodological quality of the included trials by considering allocation sequence, concealment of allocation, blinding, and inclusion of all randomized participants. We used Review Manager (version 4.1) for the meta-analysis and also explored possible sources of heterogeneity.


RESULTS
Three trials with a total of 573 participants met the inclusion criteria. These trials all compared phenobarbitone with placebo or no treatment. In the two trials with adequate allocation concealment, death was more common in the anticonvulsant group (Relative Risk 2.0; 95% confidence interval 1.20 to 3.33; fixed effect model). In all three trials, phenobarbitone compared with placebo or no treatment was associated with fewer convulsions (Relative Risk 0.30; 95% confidence interval 0.19 to 0.45; fixed effect model).


CONCLUSIONS
Routine phenobarbitone in cerebral malaria is associated with fewer convulsions but possibly more deaths. Further trials with adequate design, more participants, and different doses of anticonvulsant drugs are needed.
Meremikwu
M
M
Department of Paediatrics, University of Calabar, PMB 1115, Calabar, Cross River State, Nigeria. meremiku@skannet.com
Marson
A G
AG
D000927:Anticonvulsants / Q000627:therapeutic use*; D006801:Humans; D016779:Malaria, Cerebral / Q000188:drug therapy* / Q000401:mortality; D010634:Phenobarbital / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012640:Seizures / Q000188:drug therapy* / Q000401:mortality
D000927:Anticonvulsants; D010634:Phenobarbital